Ipilimumab/nivolumabDermatitis, transaminitis and thyroid disorders: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1712卷 / 1期

关键词：

D O I：

10.1007/s40278-018-49595-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：306 / 306

相关论文

共 50 条

[1] Ipilimumab/nivolumabDermatitis, colitis and hepatitis: case report
[J]. Reactions Weekly, 2021, 1838 (1) : 288 - 288
[2] Ipilimumab/nivolumabDermatitis, diarrhoea and hepatitis: case report
[J]. Reactions Weekly, 2019, 1753 (1) : 202 - 202
[3] Ciclosporin/ipilimumab/nivolumabDermatitis and nephrotoxicity: case report
[J]. Reactions Weekly, 2019, 1765 (1) : 104 - 104
[4] Ipilimumab/nivolumabDermatitis, renal toxicity and pancreatitis: case report
[J]. Reactions Weekly, 2021, 1882 (1) : 254 - 254
[5] Ipilimumab/nivolumabEye disorders: case report
[J]. Reactions Weekly, 2019, 1764 (1) : 191 - 191
[6] Ipilimumab/hydrocortisoneMultiple disorders: case report
[J]. Reactions Weekly, 2014, 1519 (1) : 102 - 102
[7] NivolumabDermatitis, encephalitis and seizure: case report
[J]. Reactions Weekly, 2020, 1797 (1) : 187 - 187
[8] Ipilimumab/nivolumabAutoimmune disorders and exanthema: case report
[J]. Reactions Weekly, 2019, 1754 (1) : 201 - 201
[9] Ipilimumab/nivolumabPancreatic atrophy and thyroid atrophy: case report
[J]. Reactions Weekly, 2020, 1817 (1) : 183 - 183
[10] Ipilimumab/nivolumabHyperprogression of follicular thyroid cancer: case report
[J]. Reactions Weekly, 2021, 1874 (1) : 147 - 147

← 1 2 3 4 5 →